[HTML][HTML] Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies
The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is
still raging. However, the pathophysiology of acute and post-acute manifestations of COVID …
still raging. However, the pathophysiology of acute and post-acute manifestations of COVID …
[HTML][HTML] The signal pathways and treatment of cytokine storm in COVID-19
L Yang, X Xie, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …
and is more devastating than any other previous infectious disease. It has affected a …
[HTML][HTML] Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms
P Montero, J Milara, I Roger, J Cortijo - International journal of molecular …, 2021 - mdpi.com
Interstitial lung diseases (ILDs) comprise different fibrotic lung disorders characterized by
cellular proliferation, interstitial inflammation, and fibrosis. The JAK/STAT molecular pathway …
cellular proliferation, interstitial inflammation, and fibrosis. The JAK/STAT molecular pathway …
[HTML][HTML] Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases
S Kakavandi, I Zare, M VaezJalali, M Dadashi… - Cell Communication and …, 2023 - Springer
Abstract Coronavirus disease 2019 (COVID-19) is caused by a new member of the
Coronaviridae family known as severe acute respiratory syndrome coronavirus 2 (SARS …
Coronaviridae family known as severe acute respiratory syndrome coronavirus 2 (SARS …
Epithelial response to IFN‐γ promotes SARS‐CoV‐2 infection
J Heuberger, J Trimpert, D Vladimirova… - EMBO molecular …, 2021 - embopress.org
Abstract SARS‐CoV‐2, the agent that causes COVID‐19, invades epithelial cells, including
those of the respiratory and gastrointestinal mucosa, using angiotensin‐converting enzyme …
those of the respiratory and gastrointestinal mucosa, using angiotensin‐converting enzyme …
[HTML][HTML] Vanadium as potential therapeutic agent for COVID-19: A focus on its antiviral, antiinflamatory, and antihyperglycemic effects
S Semiz - Journal of Trace Elements in Medicine and Biology, 2022 - Elsevier
An increasing evidence suggests that vanadium compounds are novel potential drugs in the
treatment of diabetes, atherosclerosis, and cancer. Vanadium has also demonstrated …
treatment of diabetes, atherosclerosis, and cancer. Vanadium has also demonstrated …
[HTML][HTML] Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review
NK Jain, M Tailang, HK Jain… - Frontiers in …, 2023 - frontiersin.org
Severe cases of COVID-19 are characterized by hyperinflammation induced by cytokine
storm, ARDS leading to multiorgan failure and death. JAK-STAT signaling has been …
storm, ARDS leading to multiorgan failure and death. JAK-STAT signaling has been …
Zooming in on common immune evasion mechanisms of pathogens in phagolysosomes: potential broad-spectrum therapeutic targets against infectious diseases
The intracellular viral, bacterial, or parasitic pathogens evade the host immune challenges to
propagate and cause fatal diseases. The microbes overpower host immunity at various …
propagate and cause fatal diseases. The microbes overpower host immunity at various …
[HTML][HTML] Resveratrol as an adjunctive therapy for excessive oxidative stress in aging COVID-19 patients
MT Liao, CC Wu, SFV Wu, MC Lee, WC Hu, KW Tsai… - Antioxidants, 2021 - mdpi.com
The coronavirus disease 2019 (COVID-19) pandemic continues to burden healthcare
systems worldwide. COVID-19 symptoms are highly heterogeneous, and the patient may be …
systems worldwide. COVID-19 symptoms are highly heterogeneous, and the patient may be …
Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
R Maslennikov, V Ivashkin, E Vasilieva… - Pulmonary …, 2021 - Elsevier
Background and aim Cytokine release syndrome is a dangerous complication of the
coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety …
coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety …